Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | NRAS G12C |
| Therapy | Glecirasib |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| NRAS G12C | Advanced Solid Tumor | sensitive | Glecirasib | Preclinical - Cell culture | Actionable | In a preclinical study, Glecirasib (JAB-21822) treatment inhibited viability of cells expressing NRAS G12C in culture (PMID: 40304209). | 40304209 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (40304209) | Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312. | Full reference... |